Yeung P K
College of Pharmacy, Dalhousie University, Halifax, NS B3H-3JS, Canada.
Curr Opin Mol Ther. 2000 Jun;2(3):336-9.
AT-III LLC, a joint venture between Genzyme Transgenics (GTC) and Genzyme General, is developing transgenic recombinant human antithrombin III (rhAT-III) as a potential treatment for sepsis and other disorders involving thrombosis. It is in phase III clinical trials in the US and Europe as an anticoagulant in patients undergoing elective cardiac surgery such as cardiopulmonary bypass.
AT-III有限责任公司是Genzyme转基因公司（GTC）和Genzyme通用公司的合资企业，正在开发转基因重组人抗凝血酶III（rhAT-III），作为治疗败血症和其他涉及血栓形成疾病的潜在疗法。它在美国和欧洲正处于III期临床试验阶段，用于接受如体外循环等择期心脏手术患者的抗凝治疗。
